Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KTRA |
---|---|---|
09:32 ET | 1176 | 6.92 |
10:00 ET | 450 | 6.95 |
10:18 ET | 500 | 7.65 |
10:22 ET | 100 | 7.3311 |
10:33 ET | 137 | 7.18 |
10:38 ET | 2066 | 7.18 |
10:42 ET | 100 | 7.05 |
10:44 ET | 2200 | 7.04 |
10:45 ET | 100 | 7.175 |
10:49 ET | 100 | 7.18 |
11:00 ET | 124 | 7.13 |
11:02 ET | 1700 | 6.91 |
11:16 ET | 100 | 7.13 |
11:18 ET | 100 | 7.14 |
11:34 ET | 100 | 6.9001 |
11:54 ET | 200 | 7.0199 |
11:56 ET | 100 | 6.99 |
12:03 ET | 100 | 6.9001 |
12:06 ET | 434 | 7.0198 |
12:32 ET | 100 | 7.0227 |
12:39 ET | 897 | 6.97 |
12:44 ET | 500 | 6.9 |
12:51 ET | 315 | 6.72 |
12:53 ET | 502 | 6.51 |
12:57 ET | 100 | 6.6 |
01:00 ET | 2156 | 6.4001 |
01:02 ET | 100 | 6.485 |
01:04 ET | 300 | 6.74 |
01:09 ET | 100 | 6.61 |
01:36 ET | 959 | 6.61 |
01:40 ET | 296 | 6.5 |
01:42 ET | 6177 | 6.4 |
01:44 ET | 700 | 6.54 |
01:49 ET | 500 | 6.6237 |
01:51 ET | 988 | 6.66 |
01:54 ET | 100 | 6.74 |
01:56 ET | 600 | 6.763 |
02:02 ET | 100 | 6.87 |
02:16 ET | 4480 | 6.8104 |
02:18 ET | 1532 | 6.65 |
02:21 ET | 700 | 6.65 |
02:23 ET | 100 | 6.77 |
02:25 ET | 600 | 6.61 |
02:27 ET | 1100 | 6.7 |
02:32 ET | 1500 | 6.59 |
02:36 ET | 400 | 6.6192 |
02:38 ET | 952 | 6.66 |
02:39 ET | 2100 | 6.44 |
02:41 ET | 600 | 6.48 |
03:01 ET | 248 | 6.54 |
03:17 ET | 103 | 6.445 |
03:35 ET | 431 | 6.35 |
03:42 ET | 100 | 6.33 |
03:46 ET | 349 | 6.3299 |
03:50 ET | 690 | 6.2713 |
03:51 ET | 100 | 6.32 |
03:53 ET | 1059 | 6.41 |
04:00 ET | 300 | 6.56 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kintara Therapeutics Inc | 10.6M | -0.3x | --- |
Oncorus Inc | 10.6M | -0.1x | --- |
Cingulate Inc | 10.7M | -0.6x | --- |
Innovation Pharmaceuticals Inc | 10.8M | -1.7x | --- |
Connect Biopharma Holdings Ltd | 70.4M | 0.0x | --- |
Biomx Inc | 10.4M | -0.3x | --- |
Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to available therapies, with particular focus on orphan cancer indications. The Company’s two lead candidates include VAL-083 and REM-001. Its VAL-083 is a novel, validated, deoxyribonucleic acid (DNA) targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG) The Company’s REM-001, a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC); basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.02 |
EPS | $-19.24 |
Book Value | $9.00 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.